Materson Barry J, Garcia-Estrada Manuel, Degraff Stephane B, Preston Richard A
Clinical Pharmacology Research Unit, Division of Clinical Pharmacology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Clinical Pharmacology Research Unit, Division of Clinical Pharmacology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
J Am Soc Hypertens. 2017 Nov;11(11):704-708. doi: 10.1016/j.jash.2017.09.005. Epub 2017 Sep 21.
Prehypertension (systolic blood pressure 120-139 or diastolic blood pressure 80-89 mm Hg) confers a risk of progression to hypertension, impairment of cognitive function, increased left ventricular mass, risk of end-stage renal disease, and an association with arteriosclerosis. Recent studies provide data that could support the rationale for treating prehypertensives subjects with antihypertensive medications in addition to lifestyle modification, especially if they have concomitant cardiovascular risk factors.
高血压前期(收缩压120 - 139或舒张压80 - 89毫米汞柱)会增加进展为高血压、认知功能受损、左心室质量增加、终末期肾病风险以及与动脉硬化相关的风险。最近的研究提供的数据支持了除生活方式改变外,对高血压前期患者使用抗高血压药物治疗的理论依据,特别是当他们伴有心血管危险因素时。